What is Inventisbio?
Inventisbio is a specialized biopharmaceutical enterprise dedicated to the discovery and development of innovative drugs targeting major diseases, with a primary focus on oncology, autoimmune conditions, and metabolic disorders. The company utilizes a sophisticated R&D framework that emphasizes synthetic lethal pathways, kinase inhibition, and the modulation of tumor driver genes. With a robust pipeline that includes both launched products and multiple candidates currently undergoing clinical evaluation, Inventisbio operates at the intersection of precision medicine and high-impact therapeutic development. Its market position is defined by a commitment to addressing complex biological mechanisms, supported by a research infrastructure capable of managing the full lifecycle of drug development from preclinical discovery to commercialization.
How much funding has Inventisbio raised?
Inventisbio has raised a total of $247M across 4 funding rounds:
Series A
$11M
Series B
$19M
Series C
$70M
Series D
$147M
Series A (2016): $11M with participation from Sinopharm Capital Management
Series B (2017): $19M led by OrbiMed
Series C (2019): $70M supported by OrbiMed, Shanghai Pudong Innotek Group, Advantech Capital, Lilly Asia Ventures, and CMB International Capital
Series D (2020): $147M featuring E Fund Capital, Matrix Partner China, AIHC Capital, Dyee Capital, GL Ventures LLC, Janchor Partners Limited, and Qiming Venture Partners
Key Investors in Inventisbio
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Advantech Capital
Advantech Capital is a private equity fund focused on innovation-driven growth capital within the TMT and healthcare sectors in China.
Sinopharm Capital Management
Sinopharm Capital is a professional private equity firm under the Sinopharm Group, specializing in the medical and healthcare industry with a focus on resource integration and value creation.
What's next for Inventisbio?
Looking ahead, the strategic deployment of the $147M will be pivotal for Inventisbio as it navigates the complexities of late-stage clinical trials. The company is expected to prioritize the acceleration of its two core products currently in phase III development, aiming to secure regulatory approvals that will facilitate broader market access. Furthermore, the firm is likely to continue its investment in preclinical innovation, expanding its portfolio of candidate compounds to maintain a sustainable long-term growth engine. As the company matures, the focus will shift toward operational scaling and potential commercial partnerships, ensuring that its innovative therapeutic pipeline can effectively reach patients while delivering significant value to its stakeholders in the evolving global biopharma landscape.
See full Inventisbio company page
